R1 RCM — Debt Investor Presentation (April 2018)
57 slides from R1 RCM's debt investor presentation, Apr 17, 2018
Slide 1: Lender Presentation April 17, 2018
Lender Presentation April 17, 2018
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
2 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not
Slide 3: Use of Non-GAAP Financial Measures
3 Use of Non-GAAP Financial Measures In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain Non-GAAP financial measures, which
Slide 4: Agenda and Presenters
4 Agenda and Presenters Transaction Overview Company Overview Recent Developments Acquisition Overview Key Credit Highlights Historical Financials Syndication Overview Appendix Joe Flanagan President and Chief Executive Officer Chris Ricaurte Executive Vice President, Chief Financial
Slide 5: Transaction Overview
5 Transaction Overview On February 26, 2018, R1 RCM (“R1” or the “Company”) entered into a definitive agreement to acquire the healthcare division of Intermedix Corporation (“Intermedix”, “IMX” or the “Target”), comprised of its physician and Emergency Medical Services (“EMS”) revenue cycle manage
Slide 6: Sources & Uses and Pro Forma Capitalization
6 Sources & Uses and Pro Forma Capitalization ($ in millions) Sources Amount New Revolving Credit Facility ($25) $-- New First Lien Term Loan 270 New Subordinated PIK Toggle Notes 110 Cash from Balance Sheet 104 Total Sources $484 Uses Amount Purchase Price of Intermedix $460 Estimated Fees, Expense
Slide 7: Agenda
7 Agenda Transaction Overview Company Overview Recent Developments Acquisition Overview Key Credit Highlights Historical Financials Syndication Overview Appendix
Slide 8: R1 Introduction: Who We Are
8 Largest & most experienced independent, end- to-end provider of revenue cycle solutions $28B in Pro Forma Net Patient Revenue (“NPR”) under management 25M+ patient encounters per year 10K employees…and growing 5K+ physicians supported Strong track record for customer results Comprehensive
Slide 9: What We Do: End-to-End Capabilities
9 Order & Scheduling 1 Pre-Reg. / Financial Clearance 2 Level of Care (PAS) 5 Billing and Follow-up 9 Case Mgmt / Utilization Review 6 Under- Payments Denials Mgmt. 10 Patient Pay / Pre-Collect 12 13 Customer Service 11 Compliant Charge Capture 73 Financial Counseling End-to-End Capabilities Coding
Slide 10: Robust and Proven Operating Model Drive Value
10 Robust and Proven Operating Model Drive Value 5% 20% 30% increase in net revenue reduction in A/R days reduction in cost to collect UP TO Improved Healthcare Provider Economics EXPERIENCED TALENT PROVEN PROCESS PROPRIETARY TECHNOLOGIES ANALYTICS & ACCOUNTABILITY DIMENSIONAL VISIBILITY ASSURED STA
Slide 11: Our Approach: One Trusted Partner to Optimize the Revenue Cycle
11 Our Approach One Trusted Partner to Optimize the Revenue Cycle Comprehensive Coverage of Provider Requirements Flexible Service Models+ Revenue Cycle Phases Front Order to Intake Middle Care to Claim Back-end Claim to Payment Care Setting Acute Physician Payment Models Payor-based Fee for Service
Slide 12: How We Make Money: Contracting and Onboarding Process
12 How We Make Money Contracting and Onboarding Process How We Make Money Step 1 - Assessment:We assess the health system’s cost of revenue cycle operations and determine if additional investments are needed to run optimal RCM operations Step 2 - Contracting: Results from the assessment are used to
Slide 13: How We Make Money: Illustrative Contribution
13 How We Make Money Illustrative Contribution of $3B Net Patient Revenue (Operating Partner Model) Growth 0 – 12 Months 12 – 36 Months 36+ Months Launch Steady State Profitability Trends Up as Model is Fully Deployed Note: Example of a $3B NPR health system provided for illustrative purposes only a
Slide 14: Differentiated Player Among Industry Competitors
14 Differentiated Player Among Industry Competitors Sc al abilit y Revenue Cycle Capabilities Major end-to-end Competitors Niche Competitors Single-focus End-to-End Low High Competitive Advantages Ability to Scale – Continued growth through on-boarding of additional NPR while also delivering stron
Slide 15: Landmark Partnership with Ascension & TowerBrook
15 Landmark Partnership with Ascension & TowerBrook Strategic partnership solidifies and expands relationship with the Company’s largest customer, and transitions relationship from co-managed to full operating partnership R1 exclusive provider of RCM services and PAS to Ascension hospitals for 1
Slide 16: Agenda
16 Agenda Transaction Overview Company Overview Recent Developments Acquisition Overview Key Credit Highlights Historical Financials Syndication Overview Appendix
Slide 17: 2016 and 2017 Highlights
17 Announced new company brand and vision Listed on Nasdaq and early-adopted ASC 606 accounting Expanded Ascension relationship in Wisconsin; added Wisconsin physician business Completed buildout of commercial team to execute on strategy of continued growth Onboarded $8.5B in NPR Increas
Slide 18: FY 2018 Announcements Year-to-Date
18 Anticipate onboarding an additional $2.5B(1) of NPR to provide RCM services to physician groups under Ascension Lessons learned from onboarding executed within the last 12-18 months, and capacity/capability from Intermedix expected to allow for easier deployment and faster value creation Co
Slide 19: Onboarding Timeline
19Note1: $0.5B NPR of AMG opportunity signed May 2017. $28.3 $14.4 $4.2 $4.6 $2.2 $0.4 $2.5 Existing Deployed NPR Intermedix Acquisition Expanded Intermountain Healthcare Contract Launch Presence Health Contract Launch Ascension Phase III Launch Ascension Medical Group Pro Forma NPR Expect to deploy
Slide 20: Agenda
20 Agenda Transaction Overview Company Overview Recent Developments Acquisition Overview Key Credit Highlights Historical Financials Syndication Overview Appendix
Slide 21: Intermedix at a Glance
21 Intermedix at a Glance Scaled Platform Differentiated Capabilities Experience across settings of care End-to-End Physician RCM offering Full suite of practice management services with technology Significant investment in data analytics and automation Clinical insights platform well-posi
Slide 22: Intermedix Acquisition Extends R1's End-To-End RCM Platform
22 Intermedix Acquisition Extends R1’s End-To-End RCM Platform Strategic Fit Addresses Key Healthcare Challenges Intermedix adds deep capabilities to serve non-acute care settings at scale Buildout of integrated RCM platform addresses workflow challenges across care settings Visibility across
Slide 23: Intermedix Adds Capabilities Across the Continuum of Care
23 Intermedix Adds Meaningful Capabilities to Serve Customers Across the Continuum of Care End Market Acute Care Hospital-Based Physicians Office-Based Physicians Alternate Site Emergency Medical Services IMX IMX+
Slide 24: Target Industry Expands Total Addressable Market to $100B
24 $60 $100 $40 Acute Care Physician Segment New TAM 12% Projected CAGR through 2020 25%+ Projected CAGR through 2020 Target Industry Expands Total Addressable Market (“TAM”) to $100B(1) External RCM Spend Growing Steadily(2)… …R1 Revenue Expected to Grow Faster $ in Billions Note1: CMS NHE Projecti
Slide 25: Agenda
25 Agenda Transaction Overview Company Overview Recent Developments Acquisition Overview Key Credit Highlights Historical Financials Syndication Overview Appendix
Slide 26: Key Credit Highlights
26 Key Credit Highlights Industry Challenges Create Favorable Dynamics for Outsourced RCM4 Long-Term Contracts Support Significant Business Ramp in Near-Term1 Proven Execution Ability2 Increased Diversity in Revenue Base3 Strong and Stable Cash Flow Generation and Ability to De-lever5 Combined Busin
Slide 27: FY'17 to FY'18E Adjusted EBITDA Bridge
27 $4 $27 $50-55 $23 $8 $12 $17 ($34) $25 $15 (IMX Annualized) $15 (Synergies) FY '17 Adj. EBITDA Contractually Entitled Revenue Incentive Fees Executed Margin Improvement Expected Margin Improvement Scaling / New Contract Investment IMX Acquisition Contribution FY '18E Adj. EBITDA R1 Standalone FY’
Slide 28: Ascension CBMs Pre-Corporate Adj. EBITDA Margin Progression
28 2% 3% 2% 1% FY 2016 Pre-Corporate Adj. EBITDA Margin % Site Based Productivity Productivity Driven By Transfer of Work to Shared Services Vendor Rationalization Revenue Performance FY 2017 Pre-Corporate Adj. EBITDA Margin % Ascension CBM’s – Pre-Corp. Adj. EBITDA Margin Progression Proven Executi
Slide 29: Case Study: Pre-Corporate Adj. EBITDA Margin Progression
29 4% 3% 2% Q1 '17 Pre-Corporate Adj. EBITDA Margin % Productivity Driven By Transfer of Work to Shared Services Contractually Entitled Revenue Ramp-Up Vendor Rationalization Q4 '17 Pre-Corporate Adj. EBITDA Margin % ABM’s XYZ Case Study – Pre-Corp. Adj. EBITDA Margin Progression Proven Execution Ab
Slide 30: Acquisition Diversifies End-Market and Customer Revenue Mix
30 71% 29% Ascension Others 90% 10% Ascension Others 93% 7% Acute Non-Acute Acquisition Diversifies End-Market and Customer Revenue Mix Increased Diversity in Revenue Base3 Addition of Intermedix meaningfully enhances diversification by increasing non-Ascension revenue and expanding R1’s blue-chip
Slide 31: The Challenge: Relentless Pressure on Health Systems
31 The Challenge: Relentless Pressure on Health Systems Financial Pressures Increasing Complexity Emerging payment models Transition to ICD-10 codes Regional consolidation Integration across continuum of care IT systems lacking integration across platforms Scarcity of human capital Dec
Slide 32: Proven Track Record of Creating Value for Customers
32 AR Days(1) Performance - % Increase / (Decrease) from FY 2011 Proven Track Record of Creating Value for Customers Industry Challenges Create Favorable Dynamics for Outsourced RCM4 Source: Definitive Healthcare. Note1: Gross Accounts Receivable divided by average daily Gross Revenue. Income Statem
Slide 33: 2018 and 2020 Outlook
33 2020 Outlook $1,200 – $1,300 $115 – $155 $225 – $250 ~19% $185 – $215 ($ in millions) 2018 Outlook(2) Revenue $850 – $900 GAAP Operating Income ($30) – ($55) Adjusted EBITDA(3) $50 – $55 Adjusted EBITDA Margin ~6% Free Cash Flow(4) $10 – $20 Note1: Please refer to Appendix page 52, footnote 2, fo
Slide 34: Synergies Breakdown
34 Synergies Breakdown Combined Business Expected to Generate Significant Cost Synergies6 Operational Move operations associates to India / Lithuania; $35K-$50K in annual cost savings per associate Replace IMX India vendors with R1 India associates Real Estate Close and consolidate certain sit
Slide 35: Operating Team with Demonstrated Track Record
35 Operating Team with Demonstrated Track Record Tenured, Experienced Management Team7 Joe Flanagan – President & CEO Joined June 2013; CEO since Q2’16 Extensive experience building technology driven, scalable commercial infrastructure in industrial and services sectors 20+ years of management
Slide 36: Agenda
36 Agenda Transaction Overview Company Overview Recent Developments Acquisition Overview Key Credit Highlights Historical Financials Syndication Overview Appendix
Slide 37: R1 Historical Financials
37 Historical Financials R1 Historical Financials (Non-GAAP) FY 2017 vs FY 2016 Revenue: Increased 115.5%, primarily driven by the onboarding of new Ascension hospitals under the new contract signed in February of 2016. The transition of Ascension hospitals served prior to 2016 also contributed to
Slide 38: Intermedix Historical Financials
38 Historical Financials Intermedix Historical Financials (Healthcare Segment) FY 2017 vs FY 2016 Revenue: Declined 4.6%, primarily driven by customer attrition within Practice Management and Emergency Department segments, attributable to industry consolidation. Partially offset by increases in Of
Slide 39: Strong Financial Trajectory FY 2016 – FY 2020E
39 Strong Financial Trajectory FY 2016 – FY 2020E Expected Business Ramp $209 ($27) $450 $4 $850 - $900 $50-$55 $30 $1,200 - $1,300 $225- $250 FY 2016(1) Note: Adjusted EBITDA is a Non-GAAP measure, please refer to the Appendix for a reconciliation of Non-GAAP financial measures. Note1: 2016 numbers
Slide 40: Agenda
40 Agenda Transaction Overview Company Overview Recent Developments Acquisition Overview Key Credit Highlights Historical Financials Syndication Overview Appendix
Slide 41: Summary of Terms – New Secured Credit Facilities
41 Summary of Terms – New Secured Credit Facilities Borrower: R1 RCM Inc. (the “Borrower”) Facilities: Revolving Credit Facility First Lien Term Loan B Security: First priority lien on all assets and stock of the Borrower and the Guarantors, subject to customary exceptions Guarantors: All existing a
Slide 42: Indicative Transaction Timeline
42 Indicative Transaction Timeline Date: Key Event: Tuesday, April 17th Term Loan Lender Meeting in New York Friday, April 27th Lender Commitments Due Week of April 30th Closing and Funding Bank Holiday Sun Mon Tue Wed Thu Fri Sat 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Slide 43: Agenda
43 Agenda Transaction Overview Company Overview Recent Developments Acquisition Overview Key Credit Highlights Historical Financials Syndication Overview Appendix
Slide 44: R1 Operating Model Process Description
44 R1 Operating Model Process Description 1 Order & Scheduling Order intake & appointment scheduling Self-service for patients and providers 2 Pre-registration Fin. Clearance Obtain demographics, insurance and authorization for scheduled patients 3 Financial Counseling Comprehensive uninsured screen
Slide 45: R1 Adjusted EBITDA Reconciliation
45 R1 Adjusted EBITDA Reconciliation ($ in millions) Year Ending December 31, x Quarter Ended, 2015 2016 2017 12/31/17 Net Income (loss) (GAAP) ($84.3) $177.1 ($58.8) ($40.2) Net Interest (income) Expense (0.2) (0.3) (0.2) (0.1) Income Tax Provision (benefit) (51.6) 121.1 31.5 36.6 Depreciation and
Slide 46: Intermedix Adjusted EBITDA Reconciliation
46 Intermedix Adjusted EBITDA Reconciliation ($ in millions) Year Ended December 31, 2015 2016 2017 Net loss (1) (20.7) (14.6) (26.4) Interest expense, net 30.3 30.2 30.2 Income taxes (benefit) (12.0) (7.9) 0.4 Depreciation & Amortization 43.2 42.6 43.3 Reported EBITDA $40.8 $50.3 $47.4 Emergency Pr
Slide 47: Reconciliation of GAAP Operating Income to Non-GAAP Adj. EBITDA and Free Cash Flow
47 Reconciliation of GAAP Operating Income to Non- GAAP Adj. EBITDA and Free cash Flow Guidance Note1: Includes FY 2018 new business announcements to date, such as Intermountain Healthcare, Presence Health and AMG as well as contribution from the Intermedix acquisition assuming a Q2 2018 close. Note
Slide 48: How R1 RCM Makes Money
48 How R1 RCM Makes Money Cost Reduction Shared Service Centers Utilization and Labor Arbitrage R1 RCM operates onshore / offshore shared service centers to perform aspects of RCM operations Rebadge existing employees allowing R1 to better monitor processes and standards These scenarios provid
Slide 49: Revenue Recognition Change
49 Revenue Recognition Change On January 1, 2017 R1 adopted ASC 606 Revenue from Contracts with Customer using the modified retrospective method − ASC 606 allows us to recognize revenue as we satisfy performance obligations, rather than at contract completion Goal: Simplify financial reporting a
Slide 50: Restatement and Subsequent Delisting from NYSE
50 Restatement and Subsequent Delisting from NYSE R1 determined that customer billings, particularly incentive fees relating to certain performance metrics, did not meet the criteria for revenue recognition under GAAP Restatement Focus Areas: Timing of revenue recognition: Post-restatement (and
Slide 51: Summary of Terms – New Subordinated PIK Toggle Notes
51 Summary of Terms – New Subordinated PIK Toggle Notes Issuer: R1 RCM Inc. (the “Borrower”) Issue: Subordinated PIK Toggle Notes Security: None Guarantors: All existing and future direct or indirect wholly-owned domestic subsidiaries of the Borrower Principal Amount: $110 million Maturity: 8 years
Slide 52: Use of Non-GAAP Financial Measures
52 Use of Non-GAAP Financial Measures Note1: Due to the adoption of Topic 606 as of January 1, 2017, the Non-GAAP measure of gross and net cash generated from customer contracting activities that were utilized by the Company in 2016 and 2015 are not applicable for 2017. Gross and net cash generated
Slide 53: Definitions of Non-GAAP Financial Measures
53 Definitions of Non-GAAP Financial Measures Gross cash generated from customer contracting activities is defined as GAAP net services revenue, plus the change in deferred customer billings. Net cash generated from customer contracting activities is defined as net income before net interest income,
Slide 54: GAAP vs. Non-GAAP Measurement
54 GAAP vs. Non-GAAP Measurement GAAP to Non-GAAP Reconciliation 2016 and Prior 2017 Forward (Post - ASC 606) GAAP Net Income +/- Change in Deferred Billings + Incentive Fees Cash Collected + Interest, depreciation, amortization, income taxes + Certain other adjustments (i.e. stock comp, r
Slide 55: Reconciliation of Net Service Revenue to Non-GAAP Gross Cash Generated
55 Reconciliation of Net Service Revenue to Non-GAAP Gross Cash Generated from Customer Contracting ($ in millions) Year Ending December 31, 2016, Net Services Revenue (+) Change in deferred customer billings = Gross cash generated RCM Services: Net Operating Fees $368.8 ($218.3) $150.5 RCM Services
Slide 56: Reconciliation of Net Income to Non-GAAP Net Cash Generated
56 Reconciliation of Net Income to Non-GAAP Net Cash Generated from Customer Contracting ($ in millions) Year Ending December 31, 2015 2016 Net income (loss) ($84.3) $177.1 Plus: Net interest income (0.2) (0.3) Income tax provision (benefit) (51.6) 121.1 Depreciation and amortization expense 8.5 10.
Slide 57: Reconciliation of Non-GAAP Financial Measures
57 ($ in millions) Year Ending December 31, 2015 2016 2017 Cost of services $169.0 $199.7 $416.3 Less: Share-based compensation expense 7.2 6.1 4.5 Depreciation and amortization expense 7.5 9.5 14.5 Non-GAAP cost of services $154.2 $184.1 $397.3 ($ i millions) Year Ending December 31, 2015 2016 2017